Side-by-side comparison of AI visibility scores, market position, and capabilities
Endeavor Biomedicines is a Cambridge-based clinical-stage biotech targeting drivers of fibrosis and oncology with precision small molecules; raised $450M in a 2024 Series B led by Arch Venture Partners and GV;
Endeavor Biomedicines is a clinical-stage biotechnology company founded in 2022 and headquartered in Cambridge, Massachusetts, that is developing precision small-molecule medicines targeting the molecular drivers of fibrotic diseases and cancer. The company's scientific focus is on identifying and inhibiting protein targets that are specifically activated in disease states — particularly in idiopathic pulmonary fibrosis (IPF), a fatal scarring lung disease, and solid tumor oncology. Endeavor's platform emphasizes structural biology and medicinal chemistry to design compounds with high selectivity for disease-driving targets, minimizing off-target effects that have limited the tolerability of earlier investigational drugs. The company is led by CEO Tomas Kiselak and supported by a scientific advisory board of leading experts in fibrosis and cancer biology.
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.